We recently compiled a list of the 10 Best Guru Stocks To Buy Now. In this article, we will have a look at where Roivant ...

Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, ...

Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion, the companies announced ...

Top of the morning to you and a fine one it is. Blue skies, cool breezes and plenty of chirping birds are enveloping the ...

Roivant is once again reaping the benefits of its bespoke business model. This time, it's selling Dermavant to Organon for up ...

Shares of Roivant, which owns 86% of Dermavant as of March 31, 2024, and was founded by former Republican presidential candidate Vivek Ramaswamy, were up 1.7% at $12.26 in early trading. However, ...

Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rate ...

Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...

Sen. Bernie Sanders has been probing the high prices that Novo charges for Ozempic and Wegovy. Yesterday, he share that ...

Roivant's latest biotech company launch – Pulmovant – has made its debut with a plan to develop a respiratory drug licensed ...

Roivant (ROIV) announces Pulmovant, a new Vant member to develop lung disorder therapy mosliciguat, in licensed from Bayer ...

The deal hands Organon a psoriasis and eczema cream called Vtama, while Roivant will get more cash to fund its R&D plans.